METHODS FOR THE ANALYSIS OF BREAST CANCER DISORDERS

The present invention relates to methods, arrays and computer programs for assisting in classifying breast cancer diseases. In particular the invention relates to classifying breast cancer disorders by determining the methylation status of one or more sequences according to SEQ ID NO: 1-111. The cla...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HEBBAR, PRASHANTHA, BANERJEE, NILANJANA, JANEVSKI, ANGEL, KABEKKODU, SHAMA PRASADA, KHANDIGE, SURABHI, DIMITROVA, NEVENKA, KAPAETTU, SATYAMOORTHY, GORTHI, APARNA, CHAKRABARTY, SANJIBAN, KESWARPU, PAYAL
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to methods, arrays and computer programs for assisting in classifying breast cancer diseases. In particular the invention relates to classifying breast cancer disorders by determining the methylation status of one or more sequences according to SEQ ID NO: 1-111. The classification may be further strengthened by also taking the expression levels of one or more proteins into account. La présente invention concerne des méthodes, des puces et des programmes informatiques pour aider à la classification de maladies du cancer du sein. En particulier, l'invention concerne la classification de troubles du cancer du sein en déterminant l'état de méthylation d'une ou plusieurs séquences selon SEQ ID NO: 1 à 111. La classification peut être davantage renforcée en prenant également en compte les niveaux d'expression d'une ou plusieurs protéines.